Skip Nav Destination
Issues
1 January 2016
-
Cover Image
Cover Image
The cover shows a section from a patient-derived xenograft of prostate cancer grown in mice treated with the MET/VEGFR-2 inhibitor, cabozantinib. Immunohistochemical staining shows an islet of viable tumor cells surrounding a VEGFR-2-negative blood vessel, with apoptotic cells surrounding the islet. For details, see the article by Varkaris and colleagues on page 107 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Review
Cancer Therapy: Clinical
Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
Christos Hatzis; W. Fraser Symmans; Ya Zhang; Rebekah E. Gould; Stacy L. Moulder; Kelly K. Hunt; Maysa Abu-Khalaf; Erin W. Hofstatter; Donald Lannin; Anees B. Chagpar; Lajos Pusztai
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Jatin J. Shah; Andrzej J. Jakubowiak; Owen A. O'Connor; Robert Z. Orlowski; R. Donald Harvey; Mitchell R. Smith; Daniel Lebovic; Catherine Diefenbach; Kevin Kelly; Zhaowei Hua; Allison J. Berger; George Mulligan; Hélène M. Faessel; Stephen Tirrell; Bruce J. Dezube; Sagar Lonial
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger; Barbara Jarzab; Maria E. Cabanillas; Bruce Robinson; Furio Pacini; Douglas W. Ball; Judith McCaffrey; Kate Newbold; Roger Allison; Renato G. Martins; Lisa F. Licitra; Manisha H. Shah; Donald Bodenner; Rossella Elisei; Lynn Burmeister; Yasuhiro Funahashi; Min Ren; James P. O'Brien; Steven I. Sherman
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
Masanori Noguchi; Kazumasa Matsumoto; Hirotsugu Uemura; Gaku Arai; Masatoshi Eto; Seiji Naito; Chikara Ohyama; Yasutomo Nasu; Masatoshi Tanaka; Fukuko Moriya; Shigetaka Suekane; Satoko Matsueda; Nobukazu Komatsu; Tetsuro Sasada; Akira Yamada; Tatsuyuki Kakuma; Kyogo Itoh
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Andrew H. Ko; Tanios Bekaii-Saab; Jessica Van Ziffle; Olga M. Mirzoeva; Nancy M. Joseph; AmirAli Talasaz; Peter Kuhn; Margaret A. Tempero; Eric A. Collisson; R. Kate Kelley; Alan P. Venook; Elizabeth Dito; Anna Ong; Sharvina Ziyeh; Ryan Courtin; Regina Linetskaya; Sanaa Tahiri; W. Michael Korn
Personalized Medicine and Imaging
Cancer Therapy: Preclinical
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Martin Skarzynski; Carsten U. Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E. Marti; Katherine R. Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z.H. Farooqui; Sarah E.M. Herman; Adrian Wiestner
Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors
Lukas J.A.C. Hawinkels; Amaya Garcia de Vinuesa; Madelon Paauwe; Marianna Kruithof-de Julio; Eliza Wiercinska; Evangelia Pardali; Laura Mezzanotte; Stijn Keereweer; Tanya M. Braumuller; Renier C. Heijkants; Jos Jonkers; Clemens W. Löwik; Marie-José Goumans; Timo L. ten Hagen; Peter ten Dijke
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Andreas Varkaris; Paul G. Corn; Nila U. Parikh; Eleni Efstathiou; Jian H. Song; Yu-Chen Lee; Ana Aparicio; Anh G. Hoang; Sanchaika Gaur; Lynnelle Thorpe; Sankar N. Maity; Menashe Bar Eli; Bogdan A. Czerniak; Yiping Shao; Mian Alauddin; Sue-Hwa Lin; Christopher J. Logothetis; Gary E. Gallick
Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances
Gema Perez-Chacon; Carolina Martinez-Laperche; Nerea Rebolleda; Beatriz Somovilla-Crespo; Cecilia Muñoz-Calleja; Ismael Buño; Juan M. Zapata
Biology of Human Tumors
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Siker Kimbung; in collaboration with the TEX study group; Ida Johansson; in collaboration with the TEX study group; Anna Danielsson; in collaboration with the TEX study group; Srinivas Veerla; in collaboration with the TEX study group; Suzanne Egyhazi Brage; in collaboration with the TEX study group; Marianne Frostvik Stolt; in collaboration with the TEX study group; Lambert Skoog; in collaboration with the TEX study group; Lena Carlsson; in collaboration with the TEX study group; Zakaria Einbeigi; in collaboration with the TEX study group; Elisabet Lidbrink; in collaboration with the TEX study group; Barbro Linderholm; in collaboration with the TEX study group; Niklas Loman; in collaboration with the TEX study group; Per-Olof Malmström; in collaboration with the TEX study group; Martin Söderberg; in collaboration with the TEX study group; Thomas M. Walz; in collaboration with the TEX study group; Mårten Fernö; in collaboration with the TEX study group; Thomas Hatschek; in collaboration with the TEX study group; Ingrid Hedenfalk; in collaboration with the TEX study group
PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance
Kinnari Pandya; Debra Wyatt; Brian Gallagher; Deep Shah; Andrew Baker; Jeffrey Bloodworth; Andrei Zlobin; Antonio Pannuti; Andrew Green; Ian O. Ellis; Aleksandra Filipovic; Jason Sagert; Ajay Rana; Kathy S. Albain; Lucio Miele; Mitchell F. Denning; Clodia Osipo
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS)
Florian Posch; Johannes Thaler; Gerhard-Johann Zlabinger; Oliver Königsbrügge; Silvia Koder; Christoph Zielinski; Ingrid Pabinger; Cihan Ay
Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Irena Misiewicz-Krzeminska; María E. Sarasquete; Carolina Vicente-Dueñas; Patryk Krzeminski; Katarzyna Wiktorska; Luis Antonio Corchete; Dalia Quwaider; Elizabeta A. Rojas; Rocío Corral; Ana A. Martín; Fernando Escalante; Abelardo Bárez; Juan Luis García; Isidro Sánchez-García; Ramón García-Sanz; Jesús F. San Miguel; Norma C. Gutiérrez
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Philip D. Dunne; Sonali Dasgupta; Jaine K. Blayney; Darragh G. McArt; Keara L. Redmond; Jessica-Anne Weir; Conor A. Bradley; Takehiko Sasazuki; Senji Shirasawa; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Manuel Salto-Tellez; Richard H. Wilson; Patrick G. Johnston; Sandra Van Schaeybroeck
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening
Anssi Auvinen; Sue M. Moss; Teuvo L.J. Tammela; Kimmo Taari; Monique J. Roobol; Fritz H. Schröder; Chris H. Bangma; Sigrid Carlsson; Gunnar Aus; Marco Zappa; Donella Puliti; Louis J. Denis; Vera Nelen; Maciej Kwiatkowski; Marco Randazzo; Alvaro Paez; Marcos Lujan; Jonas Hugosson
Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor
Anna Karpathakis; Harpreet Dibra; Chistodoulos Pipinikas; Andrew Feber; Tiffany Morris; Joshua Francis; Dahmane Oukrif; Dalvinder Mandair; Marinos Pericleous; Mullan Mohmaduvesh; Stefano Serra; Olagunju Ogunbiyi; Marco Novelli; TuVinh Luong; Sylvia L. Asa; Matthew Kulke; Christos Toumpanakis; Tim Meyer; Martyn Caplin; Matthew Meyerson; Stephan Beck; Christina Thirlwell
Letters to the Editor
Neoadjuvant as Future for Drug Development in Breast Cancer—Response
Angela DeMichele; on behalf of the I-SPY2 Investigators; Douglas Yee; on behalf of the I-SPY2 Investigators; Melissa Paoloni; on behalf of the I-SPY2 Investigators; Don Berry; on behalf of the I-SPY2 Investigators; Laura J. Esserman; on behalf of the I-SPY2 Investigators
Retraction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds